Biomarkers: FDA Working To Define 'Reasonably Likely To Predict' Standard
Executive Summary
CDER Director Woodcock says agency should write down its definition of a surrogate endpoint, but industry and academics will have to help with requirements for biomarker approval.
You may also be interested in...
Senate ‘Innovation’ Bill Being Narrowed With Year-End Committee Passage In Mind
The counterpart to the House Cures bill likely will focus on ‘big buckets’ of issues, including new approval pathway for antibiotics, reforms at NIH and biomarker development.
Senate ‘Innovation’ Bill Being Narrowed With Year-End Committee Passage In Mind
The counterpart to the House Cures bill likely will focus on ‘big buckets’ of issues, including new approval pathway for antibiotics, reforms at NIH and biomarker development.
FDA Patient Meeting On Huntington’s, Parkinson’s: No News Is Good News
Patient-focused drug development meetings address 'soft symptoms' and reimbursement challenges as FDA says it's familiar with most concerns aired by participants.